CalciMedica reports Q1 EPS 1c with items, consensus (67c)

Q1 EPS includes $5.6M non-cash gain from the fair value adjustment of the warrant liability. As of March 31 CalciMedica had approximately $25.7M in cash, cash equivalents and short-term investments, which, based on its current operating plan, CalciMedica expects to be sufficient to fund its operations into the second half of 2025. “This past quarter was transformational for CalciMedica. We completed enrollment in our Phase 2b CARPO trial in AP, we received FDA clearance on our IND application and started work on KOURAGE, our Phase 2 trial in patients with severe AKI, and we continued to progress our other programs, with multiple value-creating milestones on the horizon,” said Rachel Leheny, CEO. “Our progress was further supported by a private placement of up to approximately $54M including an upfront investment of $20.4M and a potential additional approximately $33.1M from accompanying warrants that trigger upon announcement of clinical trial data. We expect our cash, cash equivalents and short-term investments will provide funding into the second half of 2025. We look forward to continuing to advance our programs and to announcing topline data from CARPO later this quarter.”